July 8, 2020 6:14 PM
First Extensive Validation Study of Saphyr for Constitutional Genetic Disorders by European Consortium Shows 100% Concordance to Standard Cytogenetics and Describes Resolution of Cases of Long-Standing, Undiagnosed Disease
First large study in constitutional genetic diseases showed 100% concordance to gold-standard cytogenetic testing
In patients with leukemia, Saphyr enabled crucial discoveries including novel fusion events never described before in that disease
Saphyr solved previously unidentified genetic diseases by finding novel mutations
Making continued progress on goal to become the new standard of digital cytogenetic testing
SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that two top cytogeneticists from leading institutions in The Netherlands and France presented their research data as part of a multicentric, international effort to compare data generated with Bionano’s Saphyr system against gold standard cytogenetic methods consisting of karyotyping, FISH, and/or chromosomal microarray in patients with a variety of constitutional or inherited genetic disorders and in patients with leukemias. In back-to-back online presentations, each showed 100% concordance between Saphyr and standard cytogenetics along with other discoveries that extend the capabilities of the current standard of care.
Gisteren avond hebben ze wat gepost vandaar die voorbeurs.